The potassium binder patiromer (Veltassa) was deemed safe and well-tolerated in patients with hyperkalemia, post-marketing data showed.
Since its approval in October 2015, real-world data from the past 4 years found the sodium-free drug had a similar safety profile as it did in the clinical trials, reported Matthew Weir, MD, of the University of Maryland School of Medicine in Baltimore, in a poster at the virtual National Kidney Foundation Spring Clinical meeting. Real-world clinical experience may differ from clinical trial experience, Weir and colleagues explained. Therefore, a global pharmacovigilance database has been established to report, document, and evaluate post-marketing experience with patiromer.
Are People on Dialysis Especially Wary of the COVID-19 Vaccine? medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.
Gout treatment with pegloticase was well tolerated in a dialysis-dependent population, researchers found in a small study.
In an analysis of 42 patients with uncontrolled gout currently undergoing routine outpatient dialysis, most received on-label pegloticase (Krystexxa) consisting of biweekly infusions, with a median of three infusions, reported Anthony Bleyer, MD, of Wake Forest School of Medicine in Winston-Salem, North Carolina, and colleagues.
In total, nine patients (21%) received 12 or more pegloticase infusions, and the median interval between doses was 14 days (average of 19.5 days).
The findings were presented as a poster at the virtual National Kidney Foundation Spring Clinical Meeting. To date, we have limited literature around the use of pegloticase in chronic kidney disease patients receiving dialysis, though we know that people with chronic kidney disease are more likely to develop gout, Bleyer explained to